The mechanism of PRDX1 on Alzheimer disease

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K08069
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 52030:Psychiatry-related
• Research Institution: Gifu University
• Principal Investigator: Matsuda Shuji 岐阜大学, 大学院医学系研究科, 准教授 (70296721)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: アルツハイマー病 / BRI2 / ペプチド / PRDX1 / MHC1

Outline of Final Research Achievements

The study of Alzheimer Disease (AD) is predominantly focused on the amyloid hypothesis, which is based on the presumed toxicity of the accumulated beta amyloid deposits in brains of the patients, However, the clearance of amyloid from patients has not produced clear results. In this study, we focused on BRI2, which suppresses the processing of APP in cells and animals. We found the target of BRI2-derived peptide is PRDX1, which possibly links anti-oxidation and APP processing. Concomitantly, we found major histocompatibility antigen class I (MHCI) binds and inhibits the inhibitory function of BRI2 on APP processing.

Free Research Field

アルツハイマー病

Academic Significance and Societal Importance of the Research Achievements

現代の高齢化社会において認知症、特にアルツハイマー病（AD)は重要です。１００年ほど前に発見されたADは、現代に到るまで、病気のおこる仕組みはわかっておらず、完全に直せる薬は存在しません。ADでは中核となる遺伝子APPがあり、そのAPPが代謝されてアミロイドが脳内に沈着します。この研究ではアルツハイマー病で中核となる遺伝子APPの代謝を、一般的に考えられているものと違う角度から調べたものです。